No price history available.
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 0 | 0 | 3 | 14 | 2 | N/A | N/A |
| Operating profit | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | £m | -2 | -5 | -6 | -7 | 1 | -9 | N/A | N/A |
| EPS reported | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | £m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | £ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Futura Medical plc operates as a pharmaceutical firm specializing in the creation and advancement of consumer healthcare products. The company primarily targets the sexual health and pain management sectors. Its leading innovation is MED3000, a topical gel specifically formulated to treat erectile dysfunction. Additionally, Futura Medical offers a variety of pain relief solutions, including TPR100, a topical diclofenac gel; CBD100, a cannabidiol-based topical application; and TIB200, an ibuprofen topical gel. Established in 2001, the company is headquartered in Guildford, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Futura Medical plc operates as a pharmaceutical firm specializing in the creation and advancement of consumer healthcare products. The company primarily targets the sexual health and pain management sectors. Its leading innovation is MED3000, a topical gel specifically formulated to treat erectile dysfunction. Additionally, Futura Medical offers a variety of pain relief solutions, including TPR100, a topical diclofenac gel; CBD100, a cannabidiol-based topical application; and TIB200, an ibuprofen topical gel. Established in 2001, the company is headquartered in Guildford, United Kingdom.